Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1979 Jun;7(6):599–603. doi: 10.1111/j.1365-2125.1979.tb04649.x

Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.

J C Daubresse, D Daigneux, M Bruwier, A Luyckx, P J Lefebvre
PMCID: PMC1429683  PMID: 380614

Abstract

1. Twenty-two maturity-onset type diabetics treated with oral hypoglycaemic agents entered a single-blind crossover study using placebo (periods A and C, 2 months each) and clofibrate (2 g/day; period B; 2 months). 2. In thirteen patients, under reasonably good control, clofibrate did not reduce fasting or post-prandial blood glucose, nor 24 h glycosuria; no improvement was noted in the M-value, an index of diabetes control. 3. In contrast, in nine patients, with poor diabetes control, clofibrate reduced 24 h glycosuria and significantly improved the M-value. 4. In all patients, clofibrate therapy was associated with a significant 19-23% reduction in plasma fibrinogen. 5. It is suggested that addition of clofibrate may be useful in maturity-onset diabetics not adequately controlled by diet combined with oral hypoglycaemic agents.

Full text

PDF
599

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnett D., Craig J. G., Robinson D. S., Rogers M. P. Effect of clofibrate on glucose tolerance in maturity onset diabetes. Br J Clin Pharmacol. 1977 Aug;4(4):455–458. doi: 10.1111/j.1365-2125.1977.tb00761.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. DEMOWBRAY R. R. EXPERIENCE WITH ATROMID IN VARIOUS HYPERCHOLESTEROLAEMIC STATES AND DIABETES MELLITUS. J Atheroscler Res. 1963 Sep-Dec;3:689–693. [PubMed] [Google Scholar]
  3. Danowski T. S., Cohn R. E., Limaye N. R., Novak J. F., Saul R., Sunder J. H., Moses C. Ethyl chlorophenoxyisobutyrate (CPIB) effects in juvenile-onset diabetes mellitus. Clin Pharmacol Ther. 1965 Nov-Dec;6(6):716–730. doi: 10.1002/cpt196566716. [DOI] [PubMed] [Google Scholar]
  4. Danowski T. S., Novak J. F., Saul R. W., Vester J. W., Moses C. Hypolipidemic effect of chlorophenoxyisobutyrate in adult-onset diabetes mellitus. Clin Pharmacol Ther. 1966 Sep-Oct;7(5):631–638. doi: 10.1002/cpt196675631. [DOI] [PubMed] [Google Scholar]
  5. Daubresse J. C., Luyckx A. S., Lefebvre P. J. Letter: Potentiation of hypoglycemic effect of sulfonylureas by clofibrate. N Engl J Med. 1976 Mar 11;294(11):613–613. doi: 10.1056/NEJM197603112941118. [DOI] [PubMed] [Google Scholar]
  6. Enger S. C., Johnsen V., Samuelsen A., Laws E. A. The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease. Acta Med Scand. 1977;201(6):563–566. doi: 10.1111/j.0954-6820.1977.tb15748.x. [DOI] [PubMed] [Google Scholar]
  7. Fenderson R. W., Jr, Sekowski I., Mohan C., Deutsch S., Benjamin F., Samuel P. Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia. Am J Clin Nutr. 1974 Jan;27(1):22–28. doi: 10.1093/ajcn/27.1.22. [DOI] [PubMed] [Google Scholar]
  8. Ferrari C., Frezzati S., Romussi M., Bertazzoni A., Testori G. P., Antonini S., Paracchi A. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia. Metabolism. 1977 Feb;26(2):129–139. doi: 10.1016/0026-0495(77)90048-8. [DOI] [PubMed] [Google Scholar]
  9. HERRIOT S. C., PERCY-ROBB I. W., STRONG J. A., THOMSON C. G. THE EFFECT OF ATROMID ON SERUM CHOLESTEROL AND GLUCOSE TOLERANCE IN DIABETES MELLITUS. J Atheroscler Res. 1963 Sep-Dec;3:679–688. doi: 10.1016/s0368-1319(63)80052-6. [DOI] [PubMed] [Google Scholar]
  10. HUGGETT A. S., NIXON D. A. Use of glucose oxidase, peroxidase, and O-dianisidine in determination of blood and urinary glucose. Lancet. 1957 Aug 24;273(6991):368–370. doi: 10.1016/s0140-6736(57)92595-3. [DOI] [PubMed] [Google Scholar]
  11. Havel R. J., Kane J. P. Drugs and lipid metabolism. Annu Rev Pharmacol. 1973;13:287–308. doi: 10.1146/annurev.pa.13.040173.001443. [DOI] [PubMed] [Google Scholar]
  12. Jain A. K., Ryan J. R., McMahon F. G. Potentiation of hypoglycemic effect of sulfonylureas by halofenate. N Engl J Med. 1975 Dec 18;293(25):1283–1286. doi: 10.1056/NEJM197512182932503. [DOI] [PubMed] [Google Scholar]
  13. Lefèbvre P., Milet J., Luyckx A. Control of diabetes: an attempt to formulate policy guidelines in a department of medicine. Diabetologia. 1974 Jun;10(3):201–204. doi: 10.1007/BF00423035. [DOI] [PubMed] [Google Scholar]
  14. MILLER R. D. ATROMID IN THE TREATMENT OF POST-CLIMACTERIC DIABETES. J Atheroscler Res. 1963 Sep-Dec;3:694–700. doi: 10.1016/s0368-1319(63)80054-x. [DOI] [PubMed] [Google Scholar]
  15. Narduzzi J. V., Danowski T. S., Weir T. F., Alley R. A., Vester J. W., Moses C. Laboratory indices in clofibrate therapy of juvenile-onset diabetes. Clin Pharmacol Ther. 1967 Nov-Dec;8(6):817–823. doi: 10.1002/cpt196786817. [DOI] [PubMed] [Google Scholar]
  16. Pontiroli A. E., Viberti G., Pozza G. Inhibitory effect of clofibrate on arginine-induced insulin secretion in chemical diabetes. Acta Diabetol Lat. 1976 May-Aug;13(3-4):107–110. doi: 10.1007/BF02581254. [DOI] [PubMed] [Google Scholar]
  17. RANDLE P. J., GARLAND P. B., HALES C. N., NEWSHOLME E. A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963 Apr 13;1(7285):785–789. doi: 10.1016/s0140-6736(63)91500-9. [DOI] [PubMed] [Google Scholar]
  18. SCHLICHTKRULL J., MUNCK O., JERSILD M. THE M-VALVE, AN INDEX OF BLOOD-SUGAR CONTROL IN DIABETICS. Acta Med Scand. 1965 Jan;177:95–102. doi: 10.1111/j.0954-6820.1965.tb01810.x. [DOI] [PubMed] [Google Scholar]
  19. Schade D. S., Eaton R. P., George S., Conway M., Kaminsky N., Sivinski J. Metabolic effects of clofibrate in insulin-dependent ketosis-prone diabetic man. Metabolism. 1978 Apr;27(4):461–468. doi: 10.1016/0026-0495(78)90100-2. [DOI] [PubMed] [Google Scholar]
  20. Schwandt P., Weisweiler P., Neureuther G., Wilkening J. Einfluss von Clofibrat auf Glukosetoleranz und Insulinsekretion bei Patienten mit endogener Hypertriglyzeridämie. MMW Munch Med Wochenschr. 1976 Mar 19;118(12):351–354. [PubMed] [Google Scholar]
  21. THORP J. M. AN EXPERIMENTAL APPROACH TO THE PROBLEM OF DISORDERED LIPID METABOLISM. J Atheroscler Res. 1963 Sep-Dec;3:351–360. doi: 10.1016/s0368-1319(63)80017-4. [DOI] [PubMed] [Google Scholar]
  22. VAN HANDEL E., ZILVERSMIT D. B. Micromethod for the direct determination of serum triglycerides. J Lab Clin Med. 1957 Jul;50(1):152–157. [PubMed] [Google Scholar]
  23. Vester J. W., Sunder J. H., Aarons J. H., Danowski T. S. Long-term monitoring during clofibrate therapy. Clin Pharmacol Ther. 1970 Sep-Oct;11(5):689–697. doi: 10.1002/cpt1970115689. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES